Winthrop Kevin L, Tanaka Yoshiya, Lee Eun Bong, Wollenhaupt Jürgen, Al Enizi Ahmad, Azevedo Valderilio F, Curtis Jeffrey R
Department of Public Health and Preventative Medicine, Oregon Health and Science University, Portland, OR, USA.
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan.
Clin Exp Rheumatol. 2022 Jan;40(1):162-172. doi: 10.55563/clinexprheumatol/cpu6r9. Epub 2021 May 28.
The risk of herpes zoster (HZ) and HZ-related complications is increased in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) relative to the general population; therefore, HZ vaccination is recommended in these patient groups. In this literature-based review, we summarise the available evidence on the use of HZ vaccines in patients with RA and PsA, and discuss strategies for managing breakthrough infection. Currently available data show suboptimal rates of HZ vaccination among these patients and highlight a need for strategies to improve HZ vaccination programmes in clinical practice. Further clinical studies are also required to optimise the use of HZ vaccines in patients with RA and PsA, particularly with regard to determining the impact of different immunosuppressive therapy regimens on vaccine immunogenicity and, ultimately, efficacy, as well as the impact of vaccination on disease activity and safety.
与普通人群相比，类风湿性关节炎（RA）和银屑病关节炎（PsA）患者发生带状疱疹（HZ）及HZ相关并发症的风险增加；因此，建议在这些患者群体中接种HZ疫苗。在本基于文献的综述中，我们总结了关于RA和PsA患者使用HZ疫苗的现有证据，并讨论了管理突破性感染的策略。目前可得的数据显示这些患者中HZ疫苗接种率未达最佳，并凸显了在临床实践中改进HZ疫苗接种计划的策略的必要性。还需要进一步的临床研究来优化RA和PsA患者中HZ疫苗的使用，特别是在确定不同免疫抑制治疗方案对疫苗免疫原性以及最终疗效的影响，以及疫苗接种对疾病活动和安全性的影响方面。
